このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Management of Acute Complicated Diverticulitis: An Assessment of Current Practices

2026年5月15日 更新者:Gabriel Liberale、Jules Bordet Institute

Acute complicated diverticulitis (ACD) is a frequent surgical emergency that can be life-threatening. It encompasses various clinical entities, including colonic perforations, abscesses (Hinchey II), fistulas, and purulent or fecal peritonitis (Hinchey III/IV). Historically, the Hartmann procedure (HP) was established as the standard of care for diffuse peritonitis, particularly in frail patients. However, this intervention is associated with high rates of permanent stomas, long-term complications, and impaired quality of life. Over the past decade, several randomized controlled trials (RCTs) have compared HP with sigmoid resection and primary anastomosis (PA), sometimes combined with a diverting ileostomy. Results from these studies, notably the LADIES and DIVERTI trials, indicate that in hemodynamically stable and immunocompetent patients, PA is associated with superior functional outcomes, fewer late complications, and higher stoma reversal rates. Other minimally invasive approaches, such as laparoscopic peritoneal lavage for Hinchey III, have also been explored, showing promise in reducing stomas and reinterventions. However, their efficacy relies on stringent patient selection, and their use is not recommended by current guidelines (e.g., HAS 2017) due to higher reintervention rates. Recent epidemiological data suggest a trend toward reducing emergency surgical interventions in favor of more conservative strategies in selected cases, such as initial medical management followed by elective surgery. In this context of diversifying therapeutic options, choosing the optimal treatment requires a delicate balance between efficacy, morbidity, mortality, quality of life, and long-term preservation of intestinal function. Despite these advances, several questions remain, particularly regarding patient selection criteria and the real-world long-term impact of these interventions. A potentially underestimated factor is the role of the operator, as a significant portion of emergency cases (nights and weekends) are handled by surgeons in training.

Primary Objective: To provide a comprehensive overview of current management strategies for acute complicated diverticulitis by identifying preferred therapeutic modalities (conservative management, emergency surgery, delayed surgery) at the HUB (Hôpital Universitaire de Bruxelles).

Secondary Objectives: To evaluate the adherence of these therapeutic approaches to international guidelines. To identify clinical and context-specific predictive factors influencing the choice of therapeutic strategy.

調査の概要

研究の種類

観察的

入学 (実際)

208

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Brussels Capital
      • Anderlecht、Brussels Capital、ベルギー、1070
        • Institut Jules Bordet

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Patients older than 18 years who were treated for acute complicated diverticulitis between January 1, 2015 and December 31, 2024 at Erasme Hospital and Institut Jules Bordet.

説明

Inclusion Criteria:

  • Patients presenting with a first episode or recurrence of acute complicated diverticulitis.
  • CT scan confirmation of a Hinchey stage ≥ Ib (including stages Ib, II, III, and IV) at admission.
  • Initial management performed within the HUB (Hôpital Universitaire de Bruxelles) network.
  • Hospital admission between January 1, 2015, and December 31, 2024.

Exclusion Criteria:

  • Uncomplicated acute diverticulitis, defined by a CT scan Hinchey stage of 0 or Ia.
  • Patients in whom the diagnosis of acute diverticulitis was ultimately ruled out during medical chart review.
  • Patients whose initial management occurred at another hospital facility (outside the HUB network).
  • Incomplete medical records preventing the reliable extraction of clinical or follow-up data.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Distribution of management strategies for acute complicated diverticulitis.
時間枠:From hospital admission up to 10 years (end of study period).
Percentage of patients treated by each of the following strategies: exclusive medical treatment, radiological drainage, immediate emergency surgery, rescue surgery following medical failure, or elective surgery.
From hospital admission up to 10 years (end of study period).

二次結果の測定

結果測定
メジャーの説明
時間枠
Surgical Procedure Type (Hartmann Procedure vs. Primary Anastomosis) based on Hinchey Classification and Clinical Status.
時間枠:Through study completion, an average of 14 days (duration of index hospitalization).
The study will evaluate the association between baseline clinical parameters (including age and immunosuppression status) and radiological severity, assessed by the Hinchey classification (stages Ib to IV on admission CT scan), with the final therapeutic choice. Logistic regression analysis will be used to identify independent predictors for: (1) failure of conservative treatment and (2) selection of surgical procedure type (Hartmann Procedure vs. Primary Anastomosis). Results will be reported as Odds Ratios (OR) with 95% Confidence Intervals.
Through study completion, an average of 14 days (duration of index hospitalization).
Success rate of conservative treatment for complicated diverticulitis.
時間枠:During index hospitalization (average of 12.4 days).
Proportion of patients successfully managed without surgery during the index hospitalization.
During index hospitalization (average of 12.4 days).
Post-operative morbidity and mortality.
時間枠:30 days post-surgery.
Percentage of patients with severe complications (Clavien-Dindo III-IV) and mortality rate at 30 days post-surgery.
30 days post-surgery.
Stoma reversal rate.
時間枠:Up to 10 years.
Percentage of patients who received a temporary stoma and successfully underwent surgical restoration of bowel continuity during the follow-up period.
Up to 10 years.
Evolution of the Rate of Laparoscopic Approach.
時間枠:Perioperative (during initial surgery).
Percentage of patients undergoing a laparoscopic approach (including converted laparoscopies) compared to open surgery. The trend will be analyzed across three time periods (2015-2017, 2018-2020, 2021-2024) to assess the adoption of minimally invasive techniques.
Perioperative (during initial surgery).
Length of Hospital Stay (LOS).
時間枠:From hospital admission to discharge (average 10-14 days).
Number of days from hospital admission to discharge. The median length of stay will be compared across the three time periods (2015-2017, 2018-2020, 2021-2024) to evaluate the impact of changing clinical practices.
From hospital admission to discharge (average 10-14 days).
Adherence to Guidelines Regarding Peritoneal Lavage.
時間枠:Perioperative (during initial surgery).
Percentage of surgical cases where peritoneal lavage was performed as a standalone treatment (without resection). The evolution of this practice will be assessed across the three time periods to evaluate adherence to international guidelines (EAES/WSES) recommending the abandonment of this technique.
Perioperative (during initial surgery).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月1日

一次修了 (実際)

2026年3月30日

研究の完了 (実際)

2026年3月30日

試験登録日

最初に提出

2026年5月11日

QC基準を満たした最初の提出物

2026年5月15日

最初の投稿 (実際)

2026年5月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月22日

QC基準を満たした最後の更新が送信されました

2026年5月15日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) will not be shared in order to protect patient confidentiality and comply with European data protection regulations (GDPR) and institutional privacy policies.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する